Odyssey Therapeutics (ODTX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, emphasizing the innate immune system.

• Pipeline includes small molecule and protein therapeutics targeting key immune signaling nodes, with lead programs in ulcerative colitis, atopic dermatitis, and systemic lupus erythematosus.

• Founded in 2021, leveraging expertise in immunobiology, medicinal chemistry, and AI/ML-driven drug discovery.

• Collaborations with major pharmaceutical companies (J&J, Pfizer, Terray) for discovery and development.

Financial performance and metrics

• Net loss of $125.9 million in 2023 and $93.4 million for the nine months ended September 30, 2024; accumulated deficit of $382.7 million as of September 30, 2024.

• Cash, cash equivalents, and marketable securities of $154.9 million as of September 30, 2024.

• Revenue to date generated solely from collaboration agreements; no product sales revenue.

• Operating expenses primarily driven by R&D, with $112.3 million in 2023 and $81.1 million for the nine months ended September 30, 2024.

Use of proceeds and capital allocation

• Net proceeds from the IPO intended to fund clinical development of lead candidate OD-07656, advance IRAK4 and TNFR2 programs, support early-stage pipeline, and for general corporate purposes.

• Management retains broad discretion over use of proceeds; may also use funds for in-licensing or acquisitions.